NT-219 is under clinical development by Purple Biotech and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NT-219’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NT-219 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NT-219 overview

NT-219 is under development for the treatment of metastatic solid tumors including metastatic melanoma, ovarian cancer, esophagus cancer, Gastroesophageal (GE) Junction Carcinomas, anaplastic thyroid cancer, prostate cancer, recurrent head and neck cutaneous squamous cell carcinoma (HNCSCC), colorectal adenocarcinoma uterine adenosarcoma, sarcoma, pancreatic cancer and non-small cell lung cancer. The drug candidate acts by targeting insulin receptor substrate 1/2 and STAT3. NT-219 is a new chemical entity.

It was also under development for the treatment of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease and Huntington's disease.

Purple Biotech overview

Purple Biotech, formerly known as Kitov Pharma Ltd, is a pharmaceutical company that develops novel therapies to control tumor immune evasion and drug resistance in cancer treatments. The company’s lead product candidate consensi is a non-steroidal anti-inflammatory drug is used for the treatment of osteoarthritis pain and hypertension. Its product pipeline includes CM-24 a monoclonal antibody being developed to treat non-small cell lung cancer and NT-219 a small molecule targeting head and neck cancer. The company works in partnership with Bristol Myers Squibb, Coeptis Pharmaceuticals, CSBio and Kuhnil Pharmaceuticals to develop and commercialize its pipeline products. Purple Biotech is headquartered in Tel Aviv, Israel.

Quick View NT-219 LOA Data

Report Segments
  • Innovator
Drug Name
  • NT-219
Administration Pathway
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Developers
  • Sponsor Company: Purple Biotech
  • Originator: Hebrew University of Jerusalem
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.